LungLife AI (LLAI) Share Price, News & Analysis

Company Overview

LungLife AI, Inc., a diagnostic company, researches and develops clinical diagnostic solutions for lung cancer with artificial intelligence (AI) technology in the United States and the People's Republic of China. It engages in developing LungLB, a blood-based test to stratify cancerous and benign lung nodules identified by CT scan. The company was formerly known as Cynvenio Biosystems, Inc. and changed its name to LungLife AI, Inc. in May 2019. LungLife AI, Inc. was incorporated in 2009 and is based in Thousand Oaks, California.

Key Stats

• Today's Range: 8.50 to 8.50
• 50-Day Range: 8.06 to 14
• 52-Week Range: 8.06 to 96
• Volume: 2,563 shs
• Average Volume: 25,789 shs
• Market Capitalization: £2.61 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

LLAI Stock Analysis - Frequently Asked Questions

How have LLAI shares performed this year?

LungLife AI's stock was trading at GBX 46 at the beginning of 2024. Since then, LLAI stock has decreased by 81.5% and is now trading at GBX 8.50.
View the best growth stocks for 2024 here.

How do I buy shares of LungLife AI?

Shares of LLAI stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Diagnostics & Research
• Sub-Industry: N/A
• Current Symbol: LON:LLAI
• CUSIP: N/A
• CIK: N/A
• Web: lunglifeai.com
• Phone: 805 409 9868
• Fax: N/A
• Employees: 15
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX (0.13)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: £-4,470,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -48.59%
• Return on Assets: -27.28%

Debt

• Debt-to-Equity Ratio: 2.66
• Current Ratio: 2.83
• Quick Ratio: 9.85

Sales & Book Value

• Annual Sales: £98,566.00
• Price / Sales: 26.44
• Cash Flow: GBX 3.73 per share
• Price / Cash Flow: 2.28
• Book Value: GBX 28 per share
• Price / Book: 0.30

Miscellaneous

• Outstanding Shares: 30,660,000
• Free Float: N/A
• Market Cap: £2.61 million
• Optionable: Not Optionable
• Beta: -0.30